Neuroethics and the FDA Approval of Aducanumab

Neuroethics and the FDA Approval of Aducanumab

First, Do No Harm

25/01/2022 5:28AM

Episode Synopsis "Neuroethics and the FDA Approval of Aducanumab"

In this episode, Karishma interviews Dr. Jason Karlawish, Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania Perelman School of Medicine. We discuss the bioethics of aging and Alzheimer’s as well as the recent controversial FDA approval of aducanumab to help treat Alzheimer’s disease. We explore issues from the implications of aducanumab’s approval on care and treatment of patients with Alzheimer’s, how it will impact prescribing habits, and the shared decision-making process between providers and the patient and their caregivers.

Listen "Neuroethics and the FDA Approval of Aducanumab"

More episodes of the podcast First, Do No Harm